() -Danish drugmaker Novo Nordisk and Omeros have signed a licensing deal worth up to $2.-based company's experimental drug, ...

Omeros Corporation maintained with Strong Buy rating after securing a $2.1 billion partnership with Novo Nordisk for ...

The Washington Huskies will look to make it three in a row when they battle the Michigan Wolverines in a key Big Ten matchup ...

Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

Investing.com -- Omeros Corporation (NASDAQ:OMER) stock soared 65% Wednesday after the biotech company announced a major asset purchase and license agreement with Novo Nordisk (NYSE:NVO) for its ...

Omeros' stock surged over 150% after licensing zaltenibart to Novo Nordisk for $240M upfront, plus milestones and royalties.

Ripple treasury plans a $1B XRP fund via SPAC, adding its own holdings. Move coincides with GTreasury acquisition, boosting corporate crypto adoption.

The programs have followed different trajectories this season. Ogden (14-2-0) has emerged as the top team in 3A, winning ...

Omeros stock catapulted Wednesday after Novo Nordisk agreed to pay up to $2.1 billion to license its experimental treatment.

The patient has a rash on her cheeks and nose with sparing of the nasolabial folds, in addition to involvement of the dorsal ...

The Golden Gophers have won five in a row against Nebraska and lead the all-time series 37-25-2. Minnesota (4-2, 2-1 Big Ten) ...